Farletuzumab (MORAb-003) 是一种有效的叶酸受体-α (FRα) 抑制剂。Farletuzumab 是一种治疗性人源化单克隆抗体，对 FRα 具有高亲和力。Farletuzumab 对过表达 FRα 的细胞具有生长抑制作用。Farletuzumab 可用于癌症研究。

Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a therapeutic humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer.

Liquid

Farletuzumab (MORAb-003; 0-10 μg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner.
Farletuzumab (0.1-100 μg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Farletuzumab (0-10 μg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

[1]. Ebel W, et, al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007 Mar 9;7:6.